Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -253.01% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -11.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -6.88% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -472.46% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -16.93% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -111.03% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Tandem Diabetes Care | 1.17 Bn | 597.96 Mn | 136.79 Mn | -95.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.07% |
| Dec 31, 2025 | -34.23% |
| Sep 30, 2025 | 51.10% |
| Jun 30, 2025 | 109.11% |
| Mar 31, 2025 | 20.91% |
| Dec 31, 2024 | 27.35% |
| Sep 30, 2024 | 20.23% |
| Jun 30, 2024 | 62.05% |
| Mar 31, 2024 | 6.03% |
| Dec 31, 2023 | 34.72% |
| Sep 30, 2023 | 29.39% |
| Jun 30, 2023 | 26.90% |
| Mar 31, 2023 | -40.94% |
| Dec 31, 2022 | 54.83% |
| Sep 30, 2022 | 13.88% |
| Jun 30, 2022 | 34.51% |
| Mar 31, 2022 | 88.33% |
| Dec 31, 2021 | -126.73% |
| Sep 30, 2021 | 5.74% |
| Jun 30, 2021 | -32.53% |